Pharmaceutical Commerce

Pharmaceutical Commerce magazine: Business strategies for pharma/bio success.

[Pharmaceutical Commerce @PharmaCommerce]

MFN deals, IRA negotiation, tariffs, onshoring and now CMS's GENEROUS model are all hitting the same drugs and pricing decisions. On Supply Chain Signal, Thani Jambulingam, Ph.D. unpacks the commercial environment they're creating.
https://t.co/HBgNGPi5CG

[Pharmaceutical Commerce @PharmaCommerce]

Every state Medicaid program applied to CMS's GENEROUS model, turning MFN pricing into state-invoiced rebates. 40 states have signed; CMS projects $64.3B in 10-yr savings.

How it fits with MFN, IRA, tariffs & onshoring: new Supply Chain Signal 🏭

https://t.co/HBgNGPhxN8

[Pharmaceutical Commerce @PharmaCommerce]

Agentic AI is reshaping the specialty pharmacy experience. Explore how Gifthealth combines intelligent automation with human expertise to streamline the prescription journey while keeping empathy, clinical judgment, and trust at the center. #HealthTech
https://t.co/VuvWO1ekQt

[Pharmaceutical Commerce @PharmaCommerce]

As specialty therapies become more complex, patient support must evolve beyond individual services. Discover how connected technology and human engagement can create a more coordinated, personalized patient experience. #PatientSupport
https://t.co/PkUKF9gRTm

[Pharmaceutical Commerce @PharmaCommerce]

Up to half of the world's vaccines are wasted every year, and cold chain failures are the top reason, per WHO. In a new Pharma Commerce feature, Chase Heibel breaks down where the failures happen and what's closing the gap. https://t.co/5anrYFJGhm
#Pharma

[Pharmaceutical Commerce @PharmaCommerce]

The EU's pharma reform package is expected to be signed later in 2026, and how long new drugs stay protected in Europe may depend on more than it used to. Pharmaceutical Commerce's new piece covers what US drugmakers should weigh. https://t.co/8iT4Why3OB

[Pharmaceutical Commerce @PharmaCommerce]

Novo Nordisk's 3rd AI partnership this year, now with Anthropic, targets drug discovery bottlenecks. Plus: a first-of-its-kind pharmacy suit against Express Scripts, and a new push to decarbonize pharma manufacturing's toughest emissions source.
https://t.co/wOcH9xPE6v

[Pharmaceutical Commerce @PharmaCommerce]

FDA's 12-digit NDC rule was finalized back in March. Effective date isn't until 2033. The real question isn't the software, it's whether trading partners hit readiness on the same day. https://t.co/nxDb2Qu3fj
#Pharma

[Pharmaceutical Commerce @PharmaCommerce]

Ahead of LogiPharma USA 2026, we go behind the scenes with Charleen Ring on what's new this year, plus McKesson's Chris Van Norman previews his keynote fireside chat on building resilient pharma supply chains.
https://t.co/GDTq2ZKHor

[Pharmaceutical Commerce @PharmaCommerce]

Most hub staffing decisions still ride on a volume-to-agent ratio nobody can fully defend. New software borrows call center and ER modeling to test those calls before they're locked in.

https://t.co/LFXD753PNF
#Pharma #Hubservices

[Pharmaceutical Commerce @PharmaCommerce]

Bill Roth closes out his "Great Repricing" series by testing seven long-held pharma pricing assumptions, most don't hold up. His conclusion: The US now runs on three payer economies and winners will architect for all three. https://t.co/rNAQB8F3zO

[Pharmaceutical Commerce @PharmaCommerce]

🎙️ New Pharma Pulse: DHL's new Singapore coldchain hub, a Numerof report on pharma's commercial rebuild, and FDA's accelerated nod for sevabertinib.

Listen on Audioboom, Spotify & iHeart
https://t.co/c8Pwjy2UUB

#PharmaPulse #Pharma

[Pharmaceutical Commerce @PharmaCommerce]

No single organization is running the NDC-12 transition.

Cardinal Health's Liberty Dewey on the four parallel work streams ahead, and why the biggest implementation risk sits in the handoffs between organizations, not inside any one system.
#NDC12 #FDA

https://t.co/LXTdYYifuW

[Pharmaceutical Commerce @PharmaCommerce]

Pharma's supply chain is facing a new wave of cargo theft risk, and it's not just a logistics problem.
Danny Ramon on why quality and regulatory teams need to be part of the defense, from real-time stability data to protocols for unplanned disruptions:
https://t.co/2I7zZttgVq

[Pharmaceutical Commerce @PharmaCommerce]

Payers can now see more drug prices than ever. Manufacturers' risk isn't one price point forcing a renegotiation, it's several becoming leverage at once. Know where you're exposed and have your answer ready before a payer asks, "Why not us, too?"

https://t.co/HgHiDqh4tR
#Pharma

[Pharmaceutical Commerce @PharmaCommerce]

🎙️ New Pharma Pulse is live:

→ New Medicaid drug pricing deals reportedly in the works
→ Employers pulling back on GLP-1 coverage as costs climb
→ McKesson's $2.25B bet on oncology with the Precision Medicine Group buy
Listen here: https://t.co/uI54I4hODL

[Pharmaceutical Commerce @PharmaCommerce]

51% of patients say they stare at the screen before a virtual visit. 46% want education while they wait.

Pharma's point-of-care strategy is still built for the physical waiting room. Populus' Edith Hodkinson says the real opportunity is virtual: https://t.co/STNu1bHQLZ
#Pharma

[Pharmaceutical Commerce @PharmaCommerce]

More RWE isn't the differentiator anymore, activation is. Arcadia's Sandy Leonard on why pharma's next competitive edge depends on turning real-world data into point-of-care impact: https://t.co/9X1Qa14TjE
#Pharma

[Pharmaceutical Commerce @PharmaCommerce]

Six months in, is TrumpRx delivering real savings? 84% of surveyed managed care pros haven't referred a patient to it, and most doubt it beats what insurance already covers.

AMCP's Adam Colborn breaks down the survey data with PC: https://t.co/zT6kx0GYdf

[Pharmaceutical Commerce @PharmaCommerce]

30.3% of independent pharmacists said they were considering closing in 2025. Cardinal Health's Michelle Britt breaks down the 3 forces behind the squeeze, and how owners are diversifying revenue to stay open. Watch: https://t.co/4OZHuihXEx